Clopidogrel is a prodrug anticoagulant with active metabolites that irreversibly inhibit the platelet surface GPCR P2Y12 and thus inhibit platelet activation. However, gaining an understanding of patient response has been limited due to imprecise understanding of metabolite activity and stereochemistry, and a lack of acceptable analytes for quantifying in vivo metabolite formation. Methods for the production of all bioactive metabolites of clopidogrel, their stereochemical assignment, and the development of stable analytes via three conceptually orthogonal routes are disclosed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.joc.5b00632 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!